Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'Biosimilars'
Biosimilars published presentations and documents on DocSlides.
ASBM Biosimilars US Prescribers and Biosimilars Naming
by min-jolicoeur
Kevin Olson, CEO. Industry Standard Research. Kev...
Latin American Biologics/Biosimilars Conference
by giovanna-bartolotta
Presented by . the Alliance for Safe Bioloigic . ...
Biosimilars
by lindy-dunigan
Knowledge Connect Slide Resource. This slide dec...
ASBM Biosimilars
by phoebe-click
US Prescribers and Biosimilars Naming. Kevin Olso...
Biosimilars in RA: A Blessing or a Curse?
by conchita-marotz
Introduction/Overview . What Is a Biosimilar?. Di...
US Regulatory Pathway For Biosimilars
by cheryl-pisano
Practical Legal/Regulatory Considerations Arising...
Biosimilars in the Real World
by liane-varnes
Introduction/Overview . PLANETRA Extension Study:...
Applying Biosimilars in Hematologic Cancers
by conchita-marotz
This program will include a discussion of off-lab...
Biosimilars & EU regulation
by karlyn-bohler
Alice DOMINIQUE - M2 AREIPS. 1. Content. 2. Defin...
Biosimilars are effective and safe and should immediately replace innovator molecules in the NHS
by myesha-ticknor
Dr Chris Deighton. Consultant Rheumatologist . Co...
Application of Biosimilars in RA IN Clinical Practice:
by conchita-marotz
Key Issues and Challenges. . Introduction. Diff...
Biosimilars in emerging markets- regulatory and Commercial considerations
by jane-oiler
OMIC Group. Biosimilars 2104. Hyderabad. India. 2...
Building a Biosimilars Pathway in the U.S.
by attentionallianz
Richard . Dolinar. , MD. Endocrinologist, Chairman...
Synergy Satellite Event - Biosimilars in colorectal cancer
by mia
– what's your gut feeling?. 25th Anniversary EAH...
What is the value of Real-World Evidence for Biosimilars?
by bitsy
Disclaimer. This panel is moderated by Dr. Delphin...
A QUM partnership approach to regulating
by liane-varnes
biosimilars. in Australia. David Lim, Evan Siege...
Biosimilars in the united states – Update on FDA Impleme
by test
James C. Shehan. Hyman, Phelps & McNamara, P....
Distinguishable INNs: A Global Solution
by trish-goza
Richard . Dolinar. , MD. Chairman, Alliance for S...
Acceptable changes in quality attributes of glycosylated bi
by debby-jeon
Schiestl M, Stangler T, Torella C, et al. . Nat B...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMICS Group Biosimilars 2015 Birmingham, UK. 10-1...
Understanding Biologics Biologics and Biosimilars
by calandra-battersby
Animation: What Are Biologics?. Production of Bio...
Biological Products: concepts, naming,
by faustina-dinatale
interchangeability,extrapolation. and safety. Dr...
United Spinal Association
by alida-meadow
August, 2014. Biologics & Biosimilars: . An O...
About OMICS Group OMICS Group International is an amalgamation of
by sherrill-nordquist
Open Access publications. and worldwide interna...
PhAMA Position on Biosimilar Medicines
by celsa-spraggs
Ms. Leah Goodman. Contents. Key Messages. An Over...
Bio similars A Presentation
by kittie-lecroy
By. ANSHUL . SHARMA. Graduate Research Scholar. D...
Latin American Physician Perspectives on Biosimilars
by celsa-spraggs
Presented at the . Latin American Biologics/Biosi...
CHALLENGES FACED IN THE DEVELOPMENT OF BIOSIMILARS
by iamamercy
Dr.G.Hima. . Bindu. ...
Budget impact and cost-effectiveness of oncology
by roxanne
biosimilars. Prof. dr. Steven Simoens. Health econ...
1 Immunogenicity The key safety issue for biosimilars
by gelbero
Prof. Ibrahim A. . Alsarra. Professor . of . Phar...
Category 1: Defining Terms
by jasmine
Clue: . A biologic product with no clinically mean...
Biosimilars: Additional Questions and Answers Regarding Implementatio
by mitsue-stanley
&#x/Att;¬he; [/; ott;&#xom ];&#x/BBo...
Biosimilars: Questions and Answers Regarding Implementation of the Bi
by danika-pritchard
&#x/Att;¬he; [/; ott;&#xom ];&#x/BBo...
Biosimilars: Questions and Answers Regarding Implementation of the Bi
by sherrill-nordquist
&#x/Att;¬he; [/; ott;&#xom ];&#x/BBo...
Roche Position
by faustina-dinatale
1 1 on Similar Biotherapeutic Products – B...
Biosimilars: Additional Questions and Answers Regarding Implementatio
by liane-varnes
&#x/Att;¬he; [/; ott;&#xom ];&#x/BBo...
Interchangeable Biosimilars: The Future of Affordable MedicineFDA is i
by celsa-spraggs
Interchangeability = SubstitutabilityInterchangeab...
Phil Johnson MS
by stefany-barnette
RPh. Safe School Meds, Principle Partner. Moffitt...
Biosimilars 2012 AIPLA Webinar
by stefany-barnette
September 25, 2012. 1. Denise. Kettelberger, PhD...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by stefany-barnette
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
Load More...
